Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

4.67
+0.08001.74%
Post-market: 4.670.00000.00%19:30 EDT
Volume:542.23K
Turnover:2.55M
Market Cap:146.12M
PE:-1.13
High:4.81
Open:4.58
Low:4.58
Close:4.59
52wk High:50.40
52wk Low:4.54
Shares:31.29M
Float Shares:18.39M
Volume Ratio:1.02
T/O Rate:2.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1300
EPS(LYR):-2.8503
ROE:-59.21%
ROA:-37.36%
PB:0.67
PE(LYR):-1.64

Loading ...

Analyst Reaffirms Buy on Rein Therapeutics With Unchanged $4 Target as Phase 2 IPF Trial Advances and Cash Runway Extends to 2028

TIPRANKS
·
Aug 19

Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026

GlobeNewswire
·
Aug 19

Intensity Therapeutics price target raised to $7 from $5 at H.C. Wainwright

TIPRANKS
·
Aug 19

Enliven Therapeutics Initiated at Outperform by William Blair

Dow Jones
·
Aug 18

Turn Therapeutics Reports Unregistered Cashless Warrant Share Issuance

TIPRANKS
·
Aug 18

BioMarin to Acquire Alesta Therapeutics, Expanding Skeletal Pipeline

TIPRANKS
·
Aug 18

Obsidian Therapeutics Initiated at Outperform by LifeSci Capital

Dow Jones
·
Aug 18

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors

GlobeNewswire
·
Aug 18

BlossomHill Therapeutics receives fast track designation for BH-30643 from FDA

TIPRANKS
·
Aug 18

BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC

GlobeNewswire
·
Aug 18

Barclays Initiates Enliven Therapeutics at Overweight With $78 Price Target

MT Newswires Live
·
Aug 18

Ingenia Therapeutics Goes Public on KOSDAQ

MT Newswires Live
·
Aug 18

Ingenia Therapeutics Surges in Korean Trading Debut

Dow Jones
·
Aug 18

PYC Therapeutics Schedules September Investor Webinar to Detail Pipeline Progress

TIPRANKS
·
Aug 18

Outlook Therapeutics delays quarterly SEC filing

TIPRANKS
·
Aug 18

Sangamo Therapeutics Delays Quarterly 10-Q Filing

TIPRANKS
·
Aug 18

Turn Therapeutics Raises $1.35M Through Private Placement

TIPRANKS
·
Aug 18

Akari Therapeutics Reaffirmed Buy as Analyst Keeps $27 Price Target on Advancing Trop2 ADC and Strengthened PH1 Platform

TIPRANKS
·
Aug 17

Summit Therapeutics falls -8.5%

TIPRANKS
·
Aug 17

Galera Therapeutics Inc trading halted, volatility trading pause

TIPRANKS
·
Aug 17